CTL Medical Corporation
$565.3K 315 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Maxx Orthopedics, Inc.
Maxx Orthopedics, Inc. reported $563,707.98 across General Payments, Research, and Ownership to 215 physicians and teaching hospitals across 283 transactions.
- $563.7K Above-median payer
- All-tracks total
- 283 Above-median volume
- Transactions
- 215 Above-median reach
- Recipients
- −$479.7K
- General Payments vs PY2023
Maxx Orthopedics, Inc. reported $563,707.98 across all CMS Open Payments tracks (General + Research + Ownership) to 215 physicians and teaching hospitals in Program Year 2024 - ranking #737 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $96,604.41, averaging $2.6K per recipient.
How Maxx Orthopedics, Inc.'s $563.7K all-tracks total breaks down
Maxx Orthopedics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
16/100
Total payments
F
15/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer maxx-orthopedics-inc Maxx Orthopedics, Inc.
$563.7K · #737/1,925 · 0.0% industry · PY2024
- TOT $563.7K
- RANK #737
- SHARE 0.0%
- TXN 283
- RCP 215
- CAT 2
- GEN $96.6K
- ΔGEN −$479.7K
- TOP1 13.6%
- PY 2024
Volume peers
Nearest volume peer: CTL Medical Corporation ($565.3K)
Maxx Orthopedics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Maxx Orthopedics, Inc.'s CMS-reported General Payments decreased by $479.7K (−83.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MAXX ORTHOPEDICS, INC.PY2023: MAXX ORTHOPEDICS, INC.PY2024: Maxx Orthopedics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $576,261.39
- PY2024
- $96,604.41
What the Data Shows for Maxx Orthopedics, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Maxx Orthopedics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $75.1K, accounting for 77.7% of this company's General Payments and 212 transactions.
General Payment Breakdown by Type
"Food and Beverage" leads Maxx Orthopedics, Inc.'s 2-category general-payment breakdown at $75.1K, 77.7% of the reported total.
How Maxx Orthopedics, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $75.1K | 212 | 77.7% |
| Travel and Lodging | $21.5K | 3 | 22.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $49,730.50 (51.5%) of $96,604.41 in this company's General Payments records across 67 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Maxx Orthopedics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Scott Miller
$13,123.21 across 9 reported transactions
- 2
Andrew Palmisano
$10,175.23 across 14 reported transactions
- 3
Wesley Kinzie
$9,990.38 across 10 reported transactions
- 4
Mark Munro
$8,374.95 across 1 reported transactions
- 5
SIRAJ A Sayeed
$8,066.73 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Maxx Orthopedics, Inc. ranks #737 of 1,925 by total payments (top 38% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,178 of 1,838 by HHI (bottom 36% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- BK Medical Holding Company Inc. : $164.8K total payments, HHI 693
- HEMA Biologics, LLC : $276.5K total payments, HHI 691
- Precision Spine, Inc. : $802.9K total payments, HHI 690
- Kuraray America Inc. : $352.3K total payments, HHI 690
- Ascendis Pharma Inc : $470.4K total payments, HHI 686
- Distalmotion US : $620.2K total payments, HHI 685
- Maxx Orthopedics, Inc. (this company) : $96.6K total payments, HHI 683
- Janssen Scientific Affairs, LLC : $5.7M total payments, HHI 681
- Dentsply Sirona Inc : $10.4M total payments, HHI 679
- Swedish Orphan Biovitrum Ab : $276.4K total payments, HHI 679
- Stereotaxis Inc : $15.7K total payments, HHI 679
- TheracosBio, LLC : $7.4K total payments, HHI 674
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Maxx Orthopedics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Maxx Orthopedics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Maxx Orthopedics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Expanding Innovations, Inc.
$566.5K 92 recipients
Compare payment profiles
Republic Spine
$567.3K 45 recipients
Compare payment profiles
Aesculap Biologics, LLC
$559.6K 11 recipients
Compare payment profiles
Perfuze Limited
$568.2K 6 recipients
Compare payment profiles
Hyperfine Operations, Inc.
$568.6K 56 recipients
Compare payment profiles
Put this to use
Maxx Orthopedics, Inc. ranks #737 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Maxx Orthopedics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.